サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1764299

皮膚筋炎治療の世界市場レポート 2025年

Dermatomyositis Treatment Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
皮膚筋炎治療の世界市場レポート 2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

皮膚筋炎治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）6.9％で12億米ドルに成長します。予測期間中の成長は、自己免疫疾患研究への投資の増加、新しい生物学的療法の臨床検査の増加、標的免疫抑制剤の採用拡大、バイオテクノロジー企業間の協力関係の拡大、個別化治療オプションへの需要の高まりによってもたらされます。予測期間に予想される主要動向には、標的免疫療法の進展、mRNAベースの治療法の使用拡大、新規JAK阻害剤の開発、インターフェロン経路を標的とする生物製剤の革新、個別化治療戦略の進展などがあります。

自己免疫疾患の有病率の上昇は、今後の皮膚筋炎治療市場の成長を牽引すると予想されます。自己免疫疾患は、身体の免疫系が誤って自身の健康な細胞や組織を攻撃することで発生します。このような自己免疫疾患の増加は、診断方法の進歩、認知度の向上、環境要因によって促進され、発見率の向上と報告症例の増加に寄与しています。皮膚筋炎の治療は、有害な免疫反応を抑制し、患者のQOLを向上させる標的治療を提供することで、この増加する有病率の管理に役立っています。例えば、2024年2月、米国の非営利団体であるAutoimmune Instituteは、自己免疫疾患は先進国の人口の5～10％に影響を及ぼしていると報告しました。その結果、自己免疫疾患の有病率の上昇が皮膚筋炎治療市場の拡大を後押ししています。

皮膚筋炎治療市場の主要企業は、免疫系の過剰活性に関与する特定の酵素を標的とすることで、炎症をよりよく管理するJAK阻害剤などの革新的な治療法の開拓に注力しています。JAK阻害剤はヤヌスキナーゼ酵素を阻害する薬剤であり、自己免疫疾患の症状の原因となる異常な免疫反応を減少させるのに役立ちます。例えば、米国の製薬会社Pfizerは2022年6月、皮膚筋炎患者の炎症と筋力低下を抑えることを目的とした経口JAK1とTYK2阻害剤ブレポシチニブを発表しました。この経口剤は、従来型注射療法に比べ、より簡便な選択肢を提供するものです。ブレポシチニブは疾患の根本原因に対処し、患者のQOLを高める可能性が実証されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の皮膚筋炎治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の皮膚筋炎治療市場：成長率分析
  • 世界の皮膚筋炎治療市場の実績：規模と成長、2019～2024年
  • 世界の皮膚筋炎治療市場の予測：規模と成長、2024～2029年、2034年
  • 世界の皮膚筋炎治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界の皮膚筋炎治療市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 薬剤療法
  • 免疫抑制剤
  • コルチコステロイド
  • 生物製剤
  • 理学療法
  • 世界の皮膚筋炎治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • 経口
  • 静脈内
  • 皮下
  • 世界の皮膚筋炎治療市場：患者人口統計別、実績と予測、2019～2024年、2024～2029年、2034年
  • 年齢層
  • 性別
  • 世界の皮膚筋炎治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界の皮膚筋炎治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 在宅医療
  • 専門クリニック
  • その他
  • 世界の皮膚筋炎治療市場、薬剤療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 抗マラリア薬
  • 抗ウイルス剤
  • 筋弛緩剤
  • 鎮痛剤
  • 世界の皮膚筋炎治療市場、免疫抑制剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • メトトレキサート
  • アザチオプリン
  • ミコフェノール酸モフェチル
  • シクロホスファミド
  • 世界の皮膚筋炎治療市場、コルチコステロイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • プレドニゾン
  • メチルプレドニゾロン
  • ヒドロコルチゾン
  • デキサメタゾン
  • 世界の皮膚筋炎治療市場、生物製剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • リツキシマブ
  • 静脈内免疫グロブリン（IVIG）
  • トシリズマブ
  • アバタセプト
  • 世界の皮膚筋炎治療市場、理学療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ストレッチ運動
  • 筋力トレーニング
  • 有酸素運動
  • 作業療法

第7章 地域別・国別分析

  • 世界の皮膚筋炎治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の皮膚筋炎治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 皮膚筋炎治療市場：競合情勢
  • 皮膚筋炎治療市場：企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Merck & Co. Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca plc

第31章 その他の大手企業と革新的企業

  • Novartis AG
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Amgen Inc.
  • Fresenius SE & Co. KGaA
  • Bausch Health Companies Inc.
  • BIoTest AG
  • Galapagos NV
  • argenx SE
  • Roivant Sciences Ltd.
  • Kymera Therapeutics Inc.
  • Cabaletta Bio Inc.
  • ImmunoForge Inc.
  • NovelMed Therapeutics Inc.
  • Corbus Pharmaceuticals Holdings Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 皮膚筋炎治療市場、2029年：新たな機会を提供する国
  • 皮膚筋炎治療市場、2029年：新たな機会を提供するセグメント
  • 皮膚筋炎治療市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35887

Treatment of dermatomycosis involves antifungal therapies designed to eradicate fungal skin infections. This usually includes the use of topical antifungal creams or ointments like clotrimazole, miconazole, or terbinafine for mild to moderate cases. In more severe or stubborn infections, oral antifungal drugs such as fluconazole or itraconazole may be recommended.

The primary treatment methods for dermatomyositis consist of pharmacological therapies, immunosuppressants, corticosteroids, biologics, and physical therapy. Pharmacological treatments involve the use of medications to manage, relieve, or address symptoms and root causes of the disease. These medications can be administered orally, intravenously, or subcutaneously, with patient groups categorized by age and gender. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, home care providers, specialty clinics, and other users.

The dermatomyositis treatment market research report is one of a series of new reports from The Business Research Company that provides dermatomyositis treatment market statistics, including the dermatomyositis treatment industry global market size, regional shares, competitors with the dermatomyositis treatment market share, detailed dermatomyositis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatomyositis treatment industry. This dermatomyositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dermatomyositis treatment market size has grown strongly in recent years. It will grow from $0.85 billion in 2024 to $0.91 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historical period is attributed to the rising prevalence of autoimmune diseases, increased awareness of rare inflammatory conditions, global growth in healthcare expenditure, higher diagnosis rates resulting from enhanced screening methods, and growing demand for effective alternatives to corticosteroids.

The dermatomyositis treatment market size is expected to see strong growth in the next few years. It will grow to $1.20 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The projected growth during the forecast period is driven by increasing investments in autoimmune disease research, a rise in clinical trials for new biologic therapies, greater adoption of targeted immunosuppressants, expanding collaborations among biotech companies, and growing demand for personalized treatment options. Key trends expected in the forecast period include progress in targeted immunotherapies, expanded use of mRNA-based therapies, development of new JAK inhibitors, innovations in biologics targeting interferon pathways, and advancements in personalized treatment strategies.

The rising prevalence of autoimmune diseases is anticipated to drive the growth of the dermatomyositis treatment market in the future. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues. This increase in autoimmune conditions is fueled by advancements in diagnostic methods, growing awareness, and environmental factors, which contribute to higher detection rates and more reported cases. Treatments for dermatomyositis help manage this growing prevalence by providing targeted therapies that suppress harmful immune responses and enhance patients' quality of life. For example, in February 2024, the Autoimmune Institute, a US-based nonprofit organization, reported that autoimmune diseases affect 5-10% of the population in industrialized countries. As a result, the rising prevalence of autoimmune diseases is propelling the expansion of the dermatomyositis treatment market.

Leading companies in the dermatomyositis treatment market are concentrating on developing innovative therapies, such as JAK inhibitors, to better manage inflammation by targeting specific enzymes involved in immune system overactivity. JAK inhibitors are drugs that block Janus kinase enzymes, helping to decrease the abnormal immune responses responsible for symptoms in autoimmune disorders. For example, in June 2022, Pfizer, a US-based pharmaceutical firm, introduced Brepocitinib, an oral JAK1 and TYK2 inhibitor aimed at reducing inflammation and muscle weakness in dermatomyositis patients. This oral form offers a more convenient option compared to traditional injectable therapies. Brepocitinib addresses the root causes of the disease and has demonstrated potential in enhancing patients' quality of life.

In April 2025, Syneron Bio, a biotechnology firm based in China, partnered with AstraZeneca to jointly develop and commercialize innovative oral peptide therapies targeting chronic and autoimmune diseases. This collaboration combines Syneron Bio's proprietary macrocyclic peptide technology with AstraZeneca's global expertise in drug development. AstraZeneca, headquartered in the UK, is a pharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory conditions.

Major players in the dermatomyositis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., and Corbus Pharmaceuticals Holdings Inc.

North America was the largest region in the dermatomyositis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatomycosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dermatomycosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dermatomycosis treatment market consists of revenues earned by entities by providing services such as natural and herbal remedies, antifungal shampoos, and immune-modulating treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The dermatomycosis treatment market also includes sales of antifungal nail lacquers, oral suspensions, and pediatric formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dermatomyositis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dermatomyositis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dermatomyositis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatomyositis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment Type: Pharmacological Treatments; Immunosuppressants; Corticosteroids; Biologics; Physical Therapy
  • 2) By Route Of Administration: Oral; Intravenous; Subcutaneous
  • 3) By Patient Demographics: Age Group; Gender
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Subsegments:
  • 1) By Pharmacological Treatments: Antimalarials; Antiviral Agents; Muscle Relaxants; Analgesics
  • 2) By Immunosuppressants: Methotrexate; Azathioprine; Mycophenolate Mofetil; Cyclophosphamide
  • 3) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
  • 4) By Biologics: Rituximab; Intravenous Immunoglobulin (IVIG); Tocilizumab; Abatacept
  • 5)By Physical Therapy: Stretching Exercises; Strength Training; Aerobic Conditioning; Occupational Therapy
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Bristol-Myers Squibb Company; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dermatomyositis Treatment Market Characteristics

3. Dermatomyositis Treatment Market Trends And Strategies

4. Dermatomyositis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Dermatomyositis Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Dermatomyositis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Dermatomyositis Treatment Market Growth Rate Analysis
  • 5.4. Global Dermatomyositis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Dermatomyositis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Dermatomyositis Treatment Total Addressable Market (TAM)

6. Dermatomyositis Treatment Market Segmentation

  • 6.1. Global Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmacological Treatments
  • Immunosuppressants
  • Corticosteroids
  • Biologics
  • Physical Therapy
  • 6.2. Global Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous
  • Subcutaneous
  • 6.3. Global Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Age Group
  • Gender
  • 6.4. Global Dermatomyositis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.5. Global Dermatomyositis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users
  • 6.6. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Pharmacological Treatments,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antimalarials
  • Antiviral Agents
  • Muscle Relaxants
  • Analgesics
  • 6.7. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Immunosuppressants,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Methotrexate
  • Azathioprine
  • Mycophenolate Mofetil
  • Cyclophosphamide
  • 6.8. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Corticosteroids,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prednisone
  • Methylprednisolone
  • Hydrocortisone
  • Dexamethasone
  • 6.9. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Biologics,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rituximab
  • Intravenous immunoglobulin (IVIG)
  • Tocilizumab
  • Abatacept
  • 6.10. Global Dermatomyositis Treatment Market, Sub-Segmentation Of Physical Therapy,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Stretching Exercises
  • Strength Training
  • Aerobic Conditioning
  • Occupational Therapy

7. Dermatomyositis Treatment Market Regional And Country Analysis

  • 7.1. Global Dermatomyositis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Dermatomyositis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dermatomyositis Treatment Market

  • 8.1. Asia-Pacific Dermatomyositis Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dermatomyositis Treatment Market

  • 9.1. China Dermatomyositis Treatment Market Overview
  • 9.2. China Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dermatomyositis Treatment Market

  • 10.1. India Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dermatomyositis Treatment Market

  • 11.1. Japan Dermatomyositis Treatment Market Overview
  • 11.2. Japan Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dermatomyositis Treatment Market

  • 12.1. Australia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dermatomyositis Treatment Market

  • 13.1. Indonesia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dermatomyositis Treatment Market

  • 14.1. South Korea Dermatomyositis Treatment Market Overview
  • 14.2. South Korea Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dermatomyositis Treatment Market

  • 15.1. Western Europe Dermatomyositis Treatment Market Overview
  • 15.2. Western Europe Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dermatomyositis Treatment Market

  • 16.1. UK Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dermatomyositis Treatment Market

  • 17.1. Germany Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dermatomyositis Treatment Market

  • 18.1. France Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dermatomyositis Treatment Market

  • 19.1. Italy Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dermatomyositis Treatment Market

  • 20.1. Spain Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dermatomyositis Treatment Market

  • 21.1. Eastern Europe Dermatomyositis Treatment Market Overview
  • 21.2. Eastern Europe Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dermatomyositis Treatment Market

  • 22.1. Russia Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dermatomyositis Treatment Market

  • 23.1. North America Dermatomyositis Treatment Market Overview
  • 23.2. North America Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dermatomyositis Treatment Market

  • 24.1. USA Dermatomyositis Treatment Market Overview
  • 24.2. USA Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dermatomyositis Treatment Market

  • 25.1. Canada Dermatomyositis Treatment Market Overview
  • 25.2. Canada Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dermatomyositis Treatment Market

  • 26.1. South America Dermatomyositis Treatment Market Overview
  • 26.2. South America Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dermatomyositis Treatment Market

  • 27.1. Brazil Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dermatomyositis Treatment Market

  • 28.1. Middle East Dermatomyositis Treatment Market Overview
  • 28.2. Middle East Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dermatomyositis Treatment Market

  • 29.1. Africa Dermatomyositis Treatment Market Overview
  • 29.2. Africa Dermatomyositis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Dermatomyositis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Dermatomyositis Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dermatomyositis Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Dermatomyositis Treatment Market Competitive Landscape
  • 30.2. Dermatomyositis Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Dermatomyositis Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. GlaxoSmithKline plc
  • 31.3. Eli Lilly and Company
  • 31.4. Amgen Inc.
  • 31.5. Fresenius SE & Co. KGaA
  • 31.6. Bausch Health Companies Inc.
  • 31.7. Biotest AG
  • 31.8. Galapagos NV
  • 31.9. argenx SE
  • 31.10. Roivant Sciences Ltd.
  • 31.11. Kymera Therapeutics Inc.
  • 31.12. Cabaletta Bio Inc.
  • 31.13. ImmunoForge Inc.
  • 31.14. NovelMed Therapeutics Inc.
  • 31.15. Corbus Pharmaceuticals Holdings Inc.

32. Global Dermatomyositis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dermatomyositis Treatment Market

34. Recent Developments In The Dermatomyositis Treatment Market

35. Dermatomyositis Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Dermatomyositis Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Dermatomyositis Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Dermatomyositis Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer